Evidence map›Paper›PMID 40201341›Full record

ArticleFrontiers in oncology2025

Evaluation of PDZD11 in hepatocellular carcinoma: prognostic value and diagnostic potential in combination with AFP.

Yiyun Ni, Bin Liu, Weizhen Zhang, Yilin Pang, Yaling Tian, Qingsong Lv, Shengwen Shi, Yang Zheng, Huihui Fan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yiyun NiThe Central Hospital of Yongzhou, Yongzhou Clinical College, University of South China, Yongzhou, Hunan, China.
Bin LiuThe Central Hospital of Yongzhou, Yongzhou Clinical College, University of South China, Yongzhou, Hunan, China.
Weizhen ZhangThe Central Hospital of Yongzhou, Yongzhou Clinical College, University of South China, Yongzhou, Hunan, China.
Yilin PangSchool of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yaling TianThe Central Hospital of Yongzhou, Yongzhou Clinical College, University of South China, Yongzhou, Hunan, China.
Qingsong LvThe Central Hospital of Yongzhou, Yongzhou Clinical College, University of South China, Yongzhou, Hunan, China.
Shengwen ShiThe Central Hospital of Yongzhou, Yongzhou Clinical College, University of South China, Yongzhou, Hunan, China.
Yang ZhengThe Central Hospital of Yongzhou, Yongzhou Clinical College, University of South China, Yongzhou, Hunan, China.
Huihui FanThe Central Hospital of Yongzhou, Yongzhou Clinical College, University of South China, Yongzhou, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is the most prevalent liver cancer, with a 5-year survival rate below 20% and an average survival time of 3-6 months. Identifying new biomarkers is crucial for early diagnosis and prognosis. The function of PDZ domain protein 11 (PDZD11) in HCC remains unclear. Methods: In this study, PDZD11 was investigated as a potential biomarker for HCC using bioinformatic analysis of the TCGA and ICGC datasets. Furthermore, we assessed the potential of serum PDZD11 as a clinical diagnostic marker by enrolling a cohort comprising 78 HCC patients and 62 healthy controls (HC) using the ELISA analysis and combining its expression with common tumor markers. Results: Our research found significantly higher PDZD11 mRNA expression in HCC tissues compared to tumor-adjacent tissues ( Conclusion: PDZD11 is more sensitive than AFP in assessing HCC prognosis. In conclusion, PDZD11 is a promising supplementary biomarker for HCC diagnosis and prognosis alongside AFP.

Indexed as

AFPhepatocellular carcinomaPDZD11prognosisserological biomarker

Identifiers

PMID40201341
PMCPMC11975663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.